Gurgaon, January 29, 2025 – Fortis Healthcare Limited (NSE: FORTIS, BSE: 532843) has announced that its Board of Directors will meet on February 7, 2025, to review and approve the unaudited financial results for the quarter and period ended December 31, 2024.
Key Announcements
- The financial results will cover Q3 FY25 and nine-month performance.
- The trading window remains closed until February 9, 2025, in line with SEBI’s insider trading regulations.
- The results will be submitted to BSE Limited and the National Stock Exchange of India Limited post-approval.
Regulatory Compliance & Market Expectations
Fortis Healthcare adheres to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which ensures transparency and corporate governance. Investors will analyze the company's financials in Q3 FY25 to gauge growth trends, revenue generation, and profitability.Investor Outlook
With the healthcare sector experiencing steady growth, stakeholders will be keen to examine Fortis Healthcare’s operational performance, revenue expansion, and strategic initiatives. The company’s results will highlight its market positioning and future outlook for FY25.Fortis Healthcare Limited will publish the official financial statements and disclosures on its website www.fortishealthcare.com and stock exchange platforms post-board approval.